Get the Stockscreener App
7.19
2.57%
-0.19
Relmada Therapeutics Inc stock is traded at $7.19, with a volume of 1.43M.
It is down -2.57% in the last 24 hours and up +21.66% over the past month.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
See More
Previous Close:
$7.38
Open:
$7.48
24h Volume:
1.43M
Relative Volume:
0.92
Market Cap:
$754.15M
Revenue:
-
Net Income/Loss:
$-57.39M
P/E Ratio:
-4.8918
EPS:
-1.4698
Net Cash Flow:
$-45.79M
1W Performance:
+6.52%
1M Performance:
+21.66%
6M Performance:
+272.54%
1Y Performance:
+2,290%
1-Day Range:
$7.155
$7.67
1-Week Range:
$6.84
$7.94
52-Week Range:
$0.2675
$7.94
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646 876 3459
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.925 | 2.65B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
19.76 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.85 | 351.52M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
5.67 | 301.37M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
46.01 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Initiated | Piper Sandler | Overweight |
| Jan-23-26 | Resumed | Leerink Partners | Outperform |
| Dec-22-25 | Initiated | Jefferies | Buy |
| Nov-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-05-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-05-24 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
Does Relmada Therapeutics (RLMD) have the potential to rally 75.58% as Wall Street analysts expect? - MSN
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect? - Yahoo Finance
Form PRE 14AOther preliminary proxy statements - ADVFN
[EFFECT] RELMADA THERAPEUTICS, INC. SEC Filing - Stock Titan
RLMD Stock Price, Quote & Chart | RELMADA THERAPEUTICS INC (NASDAQ:RLMD) - ChartMill
Shorts Report: Is Relmada Therapeutics Inc a speculative investmentGap Up & Trade Opportunity Analysis Reports - baoquankhu1.vn
Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale under 424B3 - Stock Titan
Aug Update: Should I invest in Relmada Therapeutics Inc before earningsM&A Rumor & Technical Confirmation Alerts - baoquankhu1.vn
Volume Recap: Does Relmada Therapeutics Inc offer margin of safety2026 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn
Trade Report: Whats next for Relmada Therapeutics Inc stock2026 WrapUp & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Mizuho reiterates Relmada stock rating on Phase 3 trial progress By Investing.com - Investing.com Australia
Mizuho reiterates Relmada stock rating on Phase 3 trial progress - Investing.com UK
Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD) - StreetInsider
Mizuho Securities Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Relmada (NASDAQ: RLMD) raises $100M, adds NDV-01 and sepranolone - Stock Titan
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research
RLMD SEC FilingsRelmada Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RLMD PE Ratio & Valuation, Is RLMD Overvalued - Intellectia AI
Relmada Therapeutics (NASDAQ: RLMD) registers 33.7M shares for resale from $160M placement - Stock Titan
Relmada Therapeutics Inc. (US75955J4022.SG) analyst ratings, estimates and forecasts - Yahoo Finance UK
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength - The Globe and Mail
RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors - MSN
Relmada Therapeutics (RLMD) price target increased by 59.26% to 14.62 - MSN
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD) - Seeking Alpha
With 20-plus years in drug development, Raj Pruthi joins PreveCeutical - Stock Titan
Relmada wins bullish view at Piper Sandler on cancer therapy - MSN
Here’s what makes Mizuho bullish on Relmada Therapeutics Inc (RLMD) stock - msn.com
Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know - MSN
Guidance Update: How do insiders feel about Relmada Therapeutics IncQuarterly Market Summary & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know - sharewise.com
Wall Street experts anticipate a potential 92.19% increase for Relmada Therapeutics (RLMD): Key Information You Need to Know - Bitget
Portfolio Update: Should I invest in Relmada Therapeutics Inc before earningsBuy Signal & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Relmada (RLMD) Q4 2025 Earnings Call Transcript - AOL.com
RLMD stock surges 42% in a week: Here's what you should know - MSN
how Fair Value analysis spotted Relmada’s 65% gain in 2024 By Investing.com - Investing.com Canada
how Fair Value analysis spotted Relmada’s 65% gain in 2024 - Investing.com
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest - MarketBeat
Piper Sandler initiates coverage of Relmada Therapeutics (RLMD) with overweight recommendation - MSN
Here’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock - Insider Monkey
Relmada Therapeutics (RLMD) Gains on Positive Analyst Coverage - GuruFocus
Relmada stock wins bullish view at Piper Sandler (RLMD:NASDAQ) - Seeking Alpha
Piper Sandler Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $12 - Moomoo
Relmada Therapeutics (NASDAQ:RLMD) Earns Overweight Rating from Analysts at Piper Sandler - MarketBeat
Piper Sandler Initiates Coverage on RLMD with Overweight Rating - GuruFocus
Relmada Therapeutics stock initiated at Overweight by Piper Sandler - Investing.com
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relmada Therapeutics Inc Stock (RLMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
Dec 15 '25 |
Buy |
4.12 |
11,665 |
48,060 |
800,000 |
| Shenouda Maged | Chief Financial Officer |
Nov 05 '25 |
Buy |
2.20 |
500,000 |
1,100,000 |
788,335 |
| Ence Chuck | CAO and COO |
Nov 05 '25 |
Buy |
2.20 |
136,000 |
299,200 |
403,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
Nov 05 '25 |
Buy |
2.20 |
272,500 |
599,500 |
1,272,500 |
| Kelly Paul Edward | Chief Operating Officer |
Nov 05 '25 |
Buy |
2.20 |
90,000 |
198,000 |
502,295 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 27 '25 |
Buy |
0.67 |
129,455 |
86,735 |
944,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
| Kelly Paul Edward | Chief Operating Officer |
May 16 '25 |
Buy |
0.43 |
200,000 |
86,060 |
412,295 |
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):